Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
imidapril + bisoprolol
- Development stage
- Unknown
- Lead developer
- Mitsubishi Tanabe Pharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Imidapril + bisoprolol is a fixed-dose combination of two antihypertensive agents used primarily for the treatment of hypertension. Imidapril is an angiotensin-converting enzyme inhibitor (ACEI) that lowers blood pressure by inhibiting the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced aldosterone secretion, and decreased blood volume. Bisoprolol is a highly selective beta-1 adrenergic receptor blocker (beta-blocker) that reduces heart rate, cardiac output, and renin release from the kidneys. The combination targets two different mechanisms in blood pressure regulation—vasoconstriction via the renin-angiotensin system and sympathetic nervous system activity—providing additive or synergistic antihypertensive effects. This combination may be particularly beneficial for patients with comorbidities such as heart failure or ischemic heart disease[2][6][7].
- Other names
- 咪达普利 + 比索洛尔
02
Targets
ACE (Angiotensin Converting Enzyme)ADRB1 (β1)
Beyond the preview
Go deeper on imidapril + bisoprolol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on imidapril + bisoprolol.